GSK/Yamanouchi Vesicare Joint Venture Unaffected By Fujisawa Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline does not expect its Vesicare joint venture with Yamanouchi to be affected by the merger between Yamanouchi and Fujisawa
You may also be interested in...
GSK New Product Launches In 2004 Will Include Vesicare, Avandaryl
GlaxoSmithKline expects that Vesicare and Avandaryl will be approved before the end of the year, the company said Sept. 14 at the Bear Stearns health care conference in New York
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?